Effects of Pitavastatin (LIVALO Tablet) on the Estimated Glomerular Filtration Rate (eGFR) in Hypercholesterolemic Patients with Chronic Kidney Disease-Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study
Effects of Pitavastatin (LIVALO Tablet) on the Estimated Glomerular Filtration Rate (eGFR) in Hypercholesterolemic Patients with Chronic Kidney Disease-Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study
复制标题
DOI：
10.5551/jat.3764
复制
发表时间：
2010-01-01
影响因子：
4.4
通讯作者：
Teramoto, Tamio
中科院分区：
文献类型：
--
作者：
Kimura, Kenjiro;Shimano, Hitoshi;Teramoto, Tamio
目的：除了进展为终末期肾病（ESRD）的风险外，已知慢性肾病（CKD）也与心血管疾病（CVD）风险升高相关。他汀类药物可改善CKD患者的肾功能。方法：LIVALO有效性和安全性（LIVES）研究数据库，一项大规模的（n = 20，279），长期（104周），匹伐他汀治疗高胆固醇血症患者的前瞻性上市后监测研究，用于评价匹伐他汀对估计肾小球滤过率（eGFR）的影响。在上述研究中招募的19，925名患者中，分析了3，119名患者的数据，以评估匹伐他汀治疗104周对eGFR的影响。在该子分析中，分析了958例基线eGFR小于60 mL/min/1.73 m（2）的患者（30.7%）。在匹伐他汀治疗104周后，观察到eGFR（+ 5.4 mL/min/1.73 m2）显著增加（p
Aim: In addition to the risk of progression to end-stage renal disease (ESRD), chronic kidney disease (CKD) is also known to be associated with an elevated risk of cardiovascular disease (CVD). Statins may improve renal function in CKD patients.Methods: The database of the LIVALO Effectiveness and Safety (LIVES) Study, a large-scale (n = 20,279), long-term (104 weeks), prospective post-marketing surveillance study of hypercholesterolemic patients treated with pitavastatin, was used to evaluate the effects of pitavastatin on the estimated glomerular filtration rate (eGFR).Results: Of the 19,925 patients enrolled in the aforementioned study, data from 3,119 patients were analyzed to evaluate the effects of pitavastatin treatment for 104 weeks on the eGFR. In this sub-analysis, 958 patients with a baseline eGFR of less than 60 mL/min/1.73 m(2) (30.7%) were analyzed. A significant increase of the eGFR (+ 5.4 mL/min/1.73 m(2)) was observed after 104 weeks of pitavastain treatment (p